Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-872-2 | CAS number: 111-46-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Carcinogenicity
Administrative data
Description of key information
Two studies investigating carcinogenic effects of the test substance are available. In the key study (Hiasa et al., 1990), the NOAEL for systemic effects was 1210 and 1160 mg/kg bw/day for males and females, respectively, based on increased drinking water consumption in both sexes and higher mortality in males. No neoplastic effects were observed up to the highest concentration. In addition no formation of bladder stones and possibly associated tumors was reported. In a second very old disregarded study (Fitzhugh and Nelson, 1946) bladder tumors occurred in high dose groups. These tumors were associated with physical irritation from bladder stones which occurred at those doses. The NOAEL was found to be 750 mg/kg bw/day. This very old study was judged as disregarded study due to limitations in documentation, especially lack of information on purity.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Principles of method if other than guideline:
- Testing for complete carcinogenicity and promoting effects.
- GLP compliance:
- no
- Specific details on test material used for the study:
- purity: 97%
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Co. Japan
- Age at study initiation: 5 weeks old
- Housing: in plastic cages, 3 males or females/cage)
- Diet: pellet diet (CRF-I : Charles River Co. Japan), ad libitum
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23 +/- 2°C
- Humidity (%): 55 +/- 5%
- Air changes (per hr): air-conditioned room - Route of administration:
- oral: drinking water
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 108 weeks
- Frequency of treatment:
- daily ad libitum
- Post exposure period:
- no
- Dose / conc.:
- 1.25 other: % DEG (nominal in water)
- Remarks:
- Equivalent to 1210 and 1160 mg/kg bw/day for males and females, respectively
- Dose / conc.:
- 2.5 other: % DEG (nominal in water)
- Remarks:
- Equivalent to 2630 and 2550 mg/kg bw/day for males and females, respectively
- No. of animals per sex per dose:
- Total 150 animals per sex
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- The dose levels used were chosen on the basis of the results of a preliminary subacute (12 weeks) experiment.
- Observations and examinations performed and frequency:
- Hematological data:
measurement of white blood cells, red blood cells, hemoglobin, hematocrit
Serum-biochemistry data:
measurement of Glutamat-Oxalacetate-Transaminase (GOT), Glutamate-Pyruvate-Transaminase (GPT), Lactatedehydrogenase (LDH), Creatine phosphokinase (CPK), urea nitrogen (BUN), uric acid (UA), Creatinine (CRE); - Sacrifice and pathology:
- Complete autopsy was performed on all animals, including those that died or were sacrificed upon becoming moribund during the experiment.
All organs were carefully examined and samples were fixed in buffered neutral 10% formalin, embedded in paraffin, and routinely stained with hemotoxylin and eosin. - Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- At week 108, survival rates of rats of both sexes treated with 93.75 mg/kg bw DEG were lower than in the other groups.
- Body weight and weight changes:
- not specified
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- DEG increased the water consumption of both males and females.
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- The analyses showed no significant differences between the treated and control rats.
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No significant differences were found between the values for the three groups.
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Description (incidence and severity):
- No carcinogenic effects were observed.
- Other effects:
- not examined
- Dose descriptor:
- NOAEL
- Effect level:
- 1 210 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- mortality
- water consumption and compound intake
- Dose descriptor:
- NOAEL
- Effect level:
- 1 160 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- mortality
- water consumption and compound intake
Reference
Organ distribution and histological diagnosis of tumors in rats treated with diethylene glycol:
No. of rats affected | |||||||
Male | Female | ||||||
Diethylene glycol conc. (%) | 0 | 1.2 | 2.5 | 0 | 1.2 | 2.5 | |
Tumor | Effective No. of rats | 47 | 47 | 40 | 48 | 45 | 45 |
No. of rats demonstrating tumor development
|
46 (97) |
46 (97) |
39 (97) |
31 (64) |
28 (62) |
26 (57) |
|
Testis |
Interstitial cell tumor |
46 (97) |
46 (97) |
39 (97) |
|
|
|
Prostate |
Adenoma |
9 (19) |
10 (21) |
2 (5) |
|
|
|
Uterus |
Endometrial polyp |
|
|
|
6 (12) |
7 (14) |
8 (197 |
Adenocarcinoma | 0 | 2 (4) | 0 | ||||
Leiomyosarcoma | 0 | 0 | 2 (4) | ||||
Mammary gland | Fibroma | 6 (12) | 4 (8) | 7 (17) | 3 (6) | 0 | 4 (8) |
Fibroadenoma | 1 (2) | 0 | 1 (2) | 4 (8) | 2 (4) | 2 (4) | |
Adenocarcinoma | 1 (2) | 0 | 1 (2) | 1 (2) | 1 (2) | 2 (4) | |
Pituitary gland | Adenoma | 5 (10) | 4 (8) | 5 (12) | 13 (27) | 14 (28) | 10 (21) |
Thyroid gland | C-cell adenoma | 9 (19) | 5 (10) | 3 (7) | 2 (4) | 6 (12) | 2 (4) |
C-cell carcinoma | 4 (8) | 5 (10) | 4 (10 | 0 | 4 (8) | 0 | |
Cyst-papillary carcinoma | 1 (2) | 0 | 0 | 0 | 0 | 0 | |
Follicular carcinoma | 0 | 0 | 0 | 0 | 1 (2) | 0 | |
Parathyroid | Adenoma | 0 | 1 (2) | 0 | 0 | 0 | 0 |
Adrenal gland | Pheochromocytoma | 6 (12) | 7 (14) | 1 (2) | 4 (8) | 0 | 2 (4) |
Malignant pheochromocytoma | 2 (4) | 3 (6) | 2 (5) | 0 | 1 82) | 2 (4) | |
Ganglioneuroma | 0 | 0 | 0 | 0 | 0 | 1 (2) | |
Pancreas | Islet cell tumor | 6 (12) | 2 (4) | 2 (5) | 2 (4) | 2 (4) | 0 |
Liver | neoplastaic nodule | 0 | 0 | 2 (5) | 0 | 0 | 0 |
Lung | Adenoma | 2 (4) | 0 | 3 (7) | 0 | 0 | 0 |
Adenocarcinoma | 1 (2) | 0 | 0 | 0 | 0 | 0 | |
Kidney | Renal cell tumor | 0 | 1 (2) | 0 | 0 | 0 | 1 (2) |
Nephroblastoma | 0 | 1 (2) | 0 | 0 | 0 | 0 | |
Peritoneum | Mesothelioma | 3 (6) | 4 (8) | 1 (2) | 0 | 1 (2) | 0 |
Haematopietic system | Leukemia | 4 (8) | 5 (10) | 2 (5) | 4 (8) | 8 (16) | 3 (6) |
Subcutis | Fibroma | 2 (4) | 2 (4) | 4 (10) | 3 (6) | 2 (4) | 2 (4) |
Preputial/clitorial gland tumor | 3 (6) | 1 (2) | 2 (5) | 3 (6) | 2 (4) | 1 (2) |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 1 160 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The available experimental test data are reliable and suitable for classification purposes under Regulation (EC) No 1272/2008. As a result the substance is not considered to be classified for carcinogenicity under Regulation (EC) No 1272/2008.
Additional information
In the key study (Hiasa et al., 1990) male and female Fischer 344 rats were administered 0, 1.25 or 2.5 % diethylene glycol in drinking water for two years after pretreatment with N-ethyl-N-hydroxyethylnitrosamine for tumor initiation. The intake of the test material was 0, 1210 or 2630 mg/kg bw/day for males and 0, 1160 or 2550 mg/kg bw/day for females.
At the high dose level drinking water consumption was clearly increased (females 17 %, males 25 %), and 19/50 males died compared to 13/50 in the control group. The serum lactate dehydrogenase activity was increased and serum urea was decreased in males, the creatine phosphokinase activity and the weights of the lung were increased in both sexes, but these changes were not reported to be clearly significant. In the urine no changes could be detected, but it was not mentioned if oxalate was measured. No bladder stones were reported. The incidences of tumors in all organs did not significantly differ between the three groups.In conclusion, this experiment did not provide evidence for a carcinogenic or kidney tumor promotion potential.
The systemic and carcinogenetic NOAEL was 1210 and 1160 mg/kg bw/day for males and females, respectively, based on increased drinking water consumption in both sexes and higher mortality in males.
In a second study, Fitzhugh and Nelson (1946) conducted a 2-year feeding study using male Osborne-Mendel rats. Doses of 0, 750, 1500 and 3000 mg/kg bw/day were used. Bladder stones composed of calcium oxalate occurred in all except one rat on the 3000 mg/kg bw/day group, and in a lesser number in those on the lower concentration. Bladder tumors occurred in about half of the rats on the 3000 and 1500 mg/kg bw/day groups, and in none of those on the 750 mg/kg bw/day group of diethylene glycol. In untreated controls there were no stones or tumors in the urinary tracts. The tumors of the bladder were both papillary and intramural. The former were generally benign, while some of the intramurally located tumors showed varying degrees of malignancy. These tumors were associated with irritation from bladder stones which occurred at those doses. Tumor formation is most likely due to secondary effects of the bladder stones and potentially linked to impurities. The NOAEL was found to be 750 mg/kg bw/day.
This study was evaluated to be not reliable as only basic information are available. More specifically no information about purity of the substance is given, which is in particular of high importance as possible impurities might strongly influence the formation of bladder stones (see below).
Summary and conclusion
The key study (Hiasa et al., 1990) clearly showed the absence of any neoplastic effects up to very high doses, which are above the recommended limit dose of 1000 mg/kg bw/day. Only systemic effects were reported. In addition no formation of bladder stones was shown.
In the second study formation of bladder stones was shown which were attributed to the formation of bladder tumors due to secondary irritating effects.
Bladder cancer formation resulting from chronic irritaion of the bladder epethelium caused by the presence of urinary calculi has been identified as a threshold effect which is also time-related due to irritation that stimulates cell division and epethelial hyperplasia. The formation of bladder stones is most likely attributed to the purity of the substance as shown in a SCCP opinion (see below, next paragraph). As no information on purity of the substance was given in this old study it was disregared.
Also, Cohen (1995, 1998) proposed that this mechanism of bladder cancer formation may be less important to humans. with any irinary crystals formed causing severe pain and leading to consultation with urologist and removal of the crystals.
In data from a SCCP Opinion the issue of bladder stone formation was further investigated. Diethylene glycol containing only 0.031 % of ethylene glycol was fed to weanlings, 2 month old, and 1 year old rats for up to 2 years at levels of 4.0 and 2.0 % in a laboratory chow. Although the weanling rats developed more bladder stones than the other groups, the difference was insignificant. The yearling rats developed their bladder stones somewhat earlier. The highest stone formation was 8 in 20 (40%) rats at the 4% dosage level. None was found in the rats fed the 2 % level. The results indicate that diethylene glycol substantially free of ethylene glycol does not cause bladder stones, suggesting that it is not metabolized to any great degree to ethylene glycol as the substance is well known to cause bladder stones (HSDB on diethylene glycol. Hazardous Substances Data Bank).
In addition data from repeated dose studies are available investigating also the formation off bladder stones (see IUCLID section 7.5). Gaunt et al.(1975) reported a 225-day oral feeding study. Male and female rats were given concentrations of 0.085, 0.17, 0.4 and 2.0 % (= 64, 128, 300, 1500 mg/kg bw/day). Dietary concentrations of 0.4 and 2.0 % resulted in oxalate crystalluria and mild defects in renal function as measured by concentration tests. The elevated levels of oxalic acid in urine in this study were considered to be a biomarker and do not indicate toxicity. Mild defects of renal function at 0.4 % diethylene glycol were therefore considered to define the NOAEL as 128 mg/kg bw/day. Generally, it should be noted, that the data on repeated dose toxicity of diethylene glycol are comparatively old and it cannot be excluded that the presence of ethylene glycol as impurity in the DEG may have influenced the results. Thus, while calcium oxalate crystals were found in the rat bladder in a 225 day experiment at 128 mg/kg bw/day, bladder stones were not observed at more than 1000 mg/kg bw/day in another study with diethylene glycol containing only 0.031% ethylene glycol.
In summary, with respect to available data from carcinogenicity, mutagenicity (please also refer to discussion on mutagenicity, chapter 5.7.3) as well as repeated dose toxicity studies indication is given that bladder stones might be formed mainly due to different impurities. Bladder stones might then induce the formation of bladder tumors as a secondary physical and chronic irritating effect seen with laboratory animals. As these effects cannot be linked to the pure diethylene glycol a classification for carcinogenicity is not justified based on the available data set and might be a secondary effect due to physical irritation cause by bladder stones.
This argumentation is in line with the conclusion on carcinogenicity reported in the Chemical hazard assessment report on DEG (NICNAS, 2009) where it is stated that that DEG did not induce bladder tumours in rats unless a foreign body or lesion was present, such as an oxalate-containing bladder stone or a surgery-induced bladder lesion (Weil et al. 1965 and 1967). These authors concluded that the bladder tumours seen were due to mechanical irritation by oxalate-containing bladder stones rather than the carcinogenic response to DEG. In more recent studies such as Ito et al. (1988), Masui (1988) and Hiasa et al. (1990* and 1991*), DEG did not demonstrate any evidence of carcinogenic effects after oral administration. Several studies in mice also showed that DEG is not carcinogenic after dermal application.
(For NICNAS report, 2009, please also refer to IUCLID Chapter 13).
In a recently conducted literature search (August 2014), no further relevant information on carcinogenicity were identified (please refer to IUCLID section 12).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
